CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 5,890,000 shares, a growth of 17.8% from the May 31st total of 5,000,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 5.0 days. Currently, 6.3% of the shares of the stock are short sold.

Institutional Trading of CureVac

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVAC. Platinum Investment Management Ltd. boosted its stake in shares of CureVac by 37.1% in the 4th quarter. Platinum Investment Management Ltd. now owns 497,906 shares of the company’s stock valued at $2,096,000 after purchasing an additional 134,626 shares during the last quarter. Jump Financial LLC bought a new stake in CureVac during the fourth quarter valued at $346,000. Tidal Investments LLC acquired a new stake in CureVac during the 1st quarter worth about $175,000. Dynamic Technology Lab Private Ltd bought a new position in shares of CureVac in the 4th quarter worth about $160,000. Finally, Aristides Capital LLC acquired a new position in shares of CureVac in the 4th quarter valued at about $100,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Stock Performance

NASDAQ CVAC opened at $3.40 on Friday. The company has a market capitalization of $761.19 million, a price-to-earnings ratio of -2.56 and a beta of 2.68. The company has a quick ratio of 2.09, a current ratio of 2.25 and a debt-to-equity ratio of 0.08. CureVac has a twelve month low of $2.21 and a twelve month high of $11.35. The stock has a fifty day simple moving average of $3.41 and a 200 day simple moving average of $3.51.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.12). CureVac had a negative net margin of 463.49% and a negative return on equity of 49.22%. The company had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. Sell-side analysts expect that CureVac will post -1.11 EPS for the current year.

Analyst Upgrades and Downgrades

CVAC has been the subject of a number of recent research reports. SVB Leerink cut CureVac from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $12.00 to $4.00 in a report on Thursday, April 25th. Leerink Partnrs downgraded CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. Finally, Guggenheim reiterated a “neutral” rating on shares of CureVac in a research report on Friday, April 5th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.